Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain. - Test2 - elhamkhani - TriplyDB

Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.

Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.

http://www.wikidata.org/entity/Q37988549

about

Comparison between Transdermal Buprenorphine and Transdermal Fentanyl for Postoperative Pain Relief after Major Abdominal Surgeries Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study.Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain.New health care measures: emphasis on better management of postsurgical pain and postoperative nausea and vomiting.Current options for providing sustained analgesia to laboratory animals.Efficacy of transdermal buprenorphine patch on post-operative pain relief after elective spinal instrumentation surgery.Work-related outcomes in randomized, double blind, placebo-controlled trials in osteoarthritis - are they adequately reported in journal publications? A systematic review

P2860

Q36476375-6C7527C7-D3AD-46F6-A801-BD2BC10E9CB7 Q36484526-37F3C22D-A097-4EBB-91AD-859B1E05A175 Q37048823-E3FD8217-9D27-46D4-9E68-07175E2B9C57 Q38190848-D8D7C957-8715-4B86-A77A-72BF2F912084 Q38252634-1E75306A-A478-4A79-AE03-0DC7C67C0C7D Q47099470-799CED4E-8F1A-400D-9A1B-6781FD446881 Q58120700-E367C26B-B3DF-48FD-8011-7B50927CA5B2

P2860

Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.

http://www.wikidata.org/entity/Q37988549

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Buprenorphine 5, 10 and 20 μg/ ...... in chronic non-malignant pain.

@en

Buprenorphine 5, 10 and 20 μg/ ...... in chronic non-malignant pain.

@nl

type

label

Buprenorphine 5, 10 and 20 μg/ ...... in chronic non-malignant pain.

@en

Buprenorphine 5, 10 and 20 μg/ ...... in chronic non-malignant pain.

@nl

prefLabel

Buprenorphine 5, 10 and 20 μg/ ...... in chronic non-malignant pain.

@en

Buprenorphine 5, 10 and 20 μg/ ...... in chronic non-malignant pain.

@nl

P1433

Q37988549-01825A01-9069-41F6-B842-6D59D334A296

P1476

Q37988549-1F033185-27B5-4A75-BD67-E4F59D899351

P2860

Q37988549-1AEBC6E5-AB49-491F-B61F-4476102DA050

Q37988549-37649258-85C7-47D5-8898-6436FCEB7AE5

Q37988549-3F9FA1C3-401A-412E-BCA2-B6364F8F1A94

Q37988549-4D888700-F72D-4E44-9181-E699868B7148

Q37988549-5BDD0DE1-736F-40C6-B1D3-AD1BA5EF3BCC

Q37988549-6CCDD302-B268-43B7-9702-C8146D5227C5

Q37988549-7012259C-8EDB-40A6-A065-F180F3D53F20

Q37988549-8B5B0670-8520-4C9B-9977-42647D985685

Q37988549-9A164D1E-6368-4136-8E8A-9A9C99704477

Q37988549-C361BEE1-59DF-4C11-84E4-80C3DD5DA851

P2888

Q37988549-D03D85D4-150B-4076-8E65-F4B91DA00735

P304

Q37988549-CB2801D8-3B2C-4617-B39F-D5409E60031F

P31

Q37988549-FA7E935B-1BB5-4977-9317-B5686377B3DC

P356

Q37988549-6F23F984-4450-4461-B7DF-9FBCBCD24745

P433

Q37988549-D6AF9B2A-2EB5-4F8B-9B96-A9FC83ECC4DF

P478

Q37988549-E9F6AF00-4939-4AFE-909A-8AAABC4E99D7

P50

Q37988549-27EF67C5-E394-4322-BFFB-29F514E9DF32

Q37988549-2BED3CBA-56B6-473C-8607-1F4BC825C06F

P577

Q37988549-E1C4270C-FEA6-484D-BCC4-C6C3BD9D06EB

P6179

Q37988549-7BBAA90F-6236-4D4C-A15E-104B5F5B9074

P698

Q37988549-7649C1F9-D288-40B5-B40D-10964B4C9447

P921

Q37988549-B123FECC-D338-41BB-92F0-E95396A281A9

P356

11208360-000000000-00000

P1433

P1476

Buprenorphine 5, 10 and 20 μg/ ...... in chronic non-malignant pain.

@en

P2860

National survey of end-of-life decisions made by UK medical practitioners.

Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.

Buprenorphine induces ceiling in respiratory depression but not in analgesia.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphon

Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.

Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.

Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial.

Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controll

Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase.

P2888

11208360-000000000-00000

P304

367-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11208360-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Katherine A Lyseng-Williamson

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1015353491

http://www.w3.org/2001/XMLSchema#string

P698

22369187

http://www.w3.org/2001/XMLSchema#string

P921